Multiple Myeloma | Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 3
Featuring perspectives from Dr Shaji Kumar, including the following topics: Introduction (0:00) Case: A woman in her early 70s with standard-risk newly diagnosed multiple myeloma (NDMM), “borderline transplant-eligible,” receiving daratumumab-RVd, with transportation limitations and missed treatments — Neil Morganstein, MD (11:50) Case: A woman in her early 50s with Stage III, high-risk NDMM (1q21+), multiple bone lesions and acute renal impairment after RVd and transplant, now on the DRAMMATIC trial — Vignesh Narayanan, MD (24:43) Cases: A man in his early 60s with relapsed t(11;14) multiple myeloma (MM) and renal failure after RVd and ASCT, now on venetoclax/bortezomib/dexamethasone and a woman in her mid 50s with high-risk t(11;14) smoldering MM — Amany R Keruakous, MD, MS and Hans Lee, MD (32:59) Case: A man in his late 70s with transplant-ineligible NDMM who received daratumumab with lenalidomide/dexamethasone but discontinued daratumumab because of a severe rash — Yanjun Ma, MD (41:32) Case: A man in his mid 80s with a history of non-muscle-invasive bladder cancer, now with multiregimen-refractory MM and biochemical disease progression — Spencer Henick Bachow, MD (45:49) CME information and select publications